Intelligence Β· Patent portfolio
United Therapeutics Europe Patents
Full USPTO pharma patent portfolio for United Therapeutics Europe β grant dates, expiration, and drug cross-links.
- Patents
- 3,720
- Expiring β€24m
- 234
Quick answer
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months β use filters for patent-cliff planning.
-
US 7252929
Methods for identifying alpha PDGFR agonists and antagonists
granted -
US 7250171
Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein
granted -
US 7247307
Vaccines against Escherichia coli O157 infection
granted -
US 7247615
Peptide agonists of prostate-specific antigen and uses therefor
granted -
US 7244724
Pyrrolobenzodiazepines
granted -
US 7244558
Production of novel Newcastle disease virus strains from cDNAs and improved live attenuated Newcastle disease vaccines
granted -
US 7235234
Bacterial delivery system
granted -
US 7235365
Specific binding agents for KSHV vIL-6 that neutralize a biological activity
granted -
US 7235228
Fluorescent-magnetic nanoparticles with core-shell structure
granted -
US 7235232
Interferon alpha hybrids
granted -
US 7235644
Vaccine against Gram-negative bacterial infections
granted -
US 7232671
Pertussis toxin gene: cloning and expression of protective antigen
granted -
US 7232890
AIB1, a novel steroid receptor co-activator
granted -
US 7232566
Methods for treating HIV infected subjects
granted -
US 7232887
Melanoma antigens and their use in diagnostic and therapeutic methods
granted -
US 7229949
Safe delivery system for agriculturally active material
granted -
US 7229963
Methods of using deacetylase inhibitors to promote cell differentiation and regeneration
granted -
US 7226991
Phenylalanine derivatives
granted -
US 7227011
Nucleic acid vaccines for prevention of flavivirus infection
granted -
US 7226602
Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
granted -
US 7227010
Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
granted -
US 7223853
Secreted frizzled related protein fragments
granted -
US 7223844
Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by Env-CD4-co-receptor complexes
granted -
US 7223836
Peptides for chlamydophila pneumoniae vaccine and diagnosis
granted -
US 7220582
Stem cells that transform to beating cardiomyocytes
granted -
US 7220852
Coronavirus isolated from humans
granted -
US 7220718
Oral treatment of hemophilia
granted -
US 7220583
Pseudomonas avr and hop proteins, their encoding nucleic acids, and use thereof
granted -
US 7220558
Cartilage-derived morphogenetic proteins
granted -
US 7220328
Low-smoke gas generating low order pressure pulse compositions
granted -
US 7220419
Self-assembling recombinant papillomavirus capsid proteins
granted -
US 7217418
Multivalent dengue virus vaccine
granted -
US 7217541
Method of making CS6 antigen vaccine for treating, preventing, or inhibiting enterotoxigenic Escherichia coli infections
granted -
US 7217811
Human gene critical to fertility
granted -
US 7217812
Extraneous DNA sequence that facilitates hantavirus gene expression
granted -
US 7214787
Recombinant vaccine against botulinum neurotoxin
granted -
US 7214524
Marek's disease virus vaccine
granted -
US 7211432
Recombinant vector expressing multiple costimulatory molecules and uses thereof
granted -
US 7211255
Contraceptives based on SP22 and SP22 antibodies
granted -
US 7211445
Conjugation of biomolecules using diels-alder cycloaddition
granted -
US 7208313
Combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
granted -
US 7208161
Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
granted -
US 7204993
Streptococcus agalactiae vaccine
granted -
US 7205334
Chondropsin-class antitumor v-atpase inhibitor compounds, compositions and methods of use thereof
granted -
US 7201907
Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines
granted -
US 7201902
Production of recombinant protein pap 31 for the diagnosis and prevention of Bartonella bacilliformis infection
granted -
US 7201911
Cloned genomes of infectious hepatitis C viruses and uses thereof
granted -
US 7199127
Purine nucleosides
granted
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory